As per attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
At the 27th AGM held on September 30, 2025, shareholders of Tyche Industries approved several board changes effective September 5, 2025. Sandeep Gokaraju was appointed as Managing Director for a 5-year term, while his brother G. Ganesh Kumar stepped down as Chairman and Managing Director to take on the role of Executive Director. Satya Srinivas Uppalapati, a mechanical engineer with over 30 years of pharmaceutical industry experience, was appointed as Executive Director. Additionally, Srinivas Gelli was redesignated from Non-Executive Director to Non-Executive Independent Director for a 5-year term, and Penumatsa Vijaya Lakshmi was re-appointed as Independent Director for a second 5-year term ending September 29, 2030.
The reshuffle keeps promoter-family control of key executive positions through two brothers (Sandeep Gokaraju and G. Ganesh Kumar), signalling leadership continuity for shareholders but reinforcing family concentration at the company's top. Re-appointments of two independent directors strengthen board continuity, while the incoming executive director brings 30+ years of pharmaceutical marketing and operations experience.